Mannose-Functionalized Nanoscaffolds for Targeted Delivery in Biomedical Applications

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Immunology

Background:

• Conventional cancer and infectious disease treatments face challenges like systemic toxicity, low drug efficacy, and drug resistance.
• Mannose-binding C-type lectins, including mannose receptor (MR, CD206) and DC-SIGN, are prevalent on cancer cells and immune cells, presenting therapeutic targets.
• Mannosylated nanomaterials show promise for targeted delivery, direct therapeutic effects, tumor microenvironment modulation, and immune stimulation.

Purpose of the Study:

• To review recent advancements in mannose-based targeted delivery nanoplatforms.
• To highlight the incorporation of various therapies within these nanoplatforms.
• To discuss their potential in cancer and infectious disease treatment.

Main Methods:

• Literature review of recent scientific publications.
• Analysis of studies focusing on mannosylated nanomaterials for targeted drug delivery.
• Synthesis of information on therapeutic applications and mechanisms.

Main Results:

• Mannosylated nanomaterials effectively target cells expressing mannose-binding lectins.
• These platforms demonstrate potential for direct therapeutic action and immune response modulation.
• The review consolidates diverse therapeutic strategies integrated with mannose-based nanodelivery systems.

Conclusions:

• Mannose-based targeted delivery nanoplatforms represent a promising strategy to overcome limitations in conventional cancer and infectious disease therapies.
• Their ability to target specific cells and modulate the immune system offers significant therapeutic potential.
• Further research into these nanoplatforms could lead to improved treatment outcomes.